Floatz logo

Fuzuloparib

Carcinoma, Non-Small-Cell Lung

Boehringer IngelheimPhase 3Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
65/ 100

Competitive context

114 Active assets in the Carcinoma, Non-Small-Cell Lung cohort.

Asset / SponsorPhaseRating
Cetuximab
Novartis Pharmaceuticals
Phase 3BB
Lazertinib
Janssen Research & Development, LLC
Phase 3BB
DEXAMETHASONE
Rigshospitalet, Denmark
Phase 4BB
Lorlatinib
Chugai Pharmaceutical
Phase 4BB
Vibostolimab
Merck Sharp & Dohme LLC
Phase 3BB

View all 50 →

Same molecule, other indications

Fuzuloparib is also rated in:

Chronic Postsurgical PainDormant
B
Indicative ·
60 / 100
View asset →
Obese Patients With Prostate Cancer DiseaseDormant
B
Indicative ·
60 / 100
View asset →
triple-negative breast carcinomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →